Future investigations incorporating primary human PAECs, patient-derived cells, and diverse animal models (including transgenic systems) will be essential to validate the therapeutic potential of eIF3a knockdown in PAH vascular remodeling. Here, EIF3A is linked to pulmonary arterial hypertension.